What is HC Wainwright’s Forecast for Vericel Q3 Earnings?

Vericel Co. (NASDAQ:VCELFree Report) – Equities research analysts at HC Wainwright lowered their Q3 2025 earnings estimates for shares of Vericel in a report released on Wednesday, January 15th. HC Wainwright analyst S. Ramakanth now forecasts that the biotechnology company will post earnings of $0.05 per share for the quarter, down from their prior estimate of $0.09. HC Wainwright currently has a “Buy” rating and a $60.00 target price on the stock. The consensus estimate for Vericel’s current full-year earnings is $0.13 per share. HC Wainwright also issued estimates for Vericel’s Q4 2025 earnings at $0.26 EPS, FY2025 earnings at $0.35 EPS, FY2026 earnings at $0.86 EPS, FY2027 earnings at $1.25 EPS and FY2028 earnings at $2.02 EPS.

Other analysts also recently issued research reports about the stock. Truist Financial raised their price target on shares of Vericel from $61.00 to $67.00 and gave the company a “buy” rating in a report on Wednesday, December 18th. Stephens restated an “overweight” rating and issued a $65.00 price target on shares of Vericel in a research note on Wednesday. BTIG Research increased their target price on Vericel from $56.00 to $66.00 and gave the company a “buy” rating in a report on Tuesday, November 26th. Canaccord Genuity Group restated a “buy” rating and set a $60.00 price target on shares of Vericel in a research note on Tuesday, November 19th. Finally, StockNews.com raised shares of Vericel from a “sell” rating to a “hold” rating in a report on Tuesday, December 24th. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $62.14.

View Our Latest Report on Vericel

Vericel Stock Performance

NASDAQ:VCEL opened at $56.35 on Friday. The firm has a 50-day simple moving average of $56.80 and a two-hundred day simple moving average of $49.89. The firm has a market cap of $2.78 billion, a P/E ratio of 939.32 and a beta of 1.72. Vericel has a fifty-two week low of $37.35 and a fifty-two week high of $61.49.

Vericel (NASDAQ:VCELGet Free Report) last posted its quarterly earnings data on Thursday, November 7th. The biotechnology company reported ($0.02) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.03. The company had revenue of $57.91 million during the quarter, compared to analyst estimates of $55.32 million. Vericel had a return on equity of 1.48% and a net margin of 1.56%.

Insider Buying and Selling at Vericel

In related news, Director Paul K. Wotton sold 2,600 shares of the stock in a transaction dated Wednesday, December 4th. The stock was sold at an average price of $58.72, for a total transaction of $152,672.00. Following the completion of the sale, the director now owns 27,402 shares in the company, valued at approximately $1,609,045.44. This trade represents a 8.67 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Robert L. Md Zerbe sold 2,500 shares of the business’s stock in a transaction that occurred on Friday, November 22nd. The stock was sold at an average price of $60.00, for a total value of $150,000.00. Following the completion of the transaction, the director now directly owns 26,595 shares in the company, valued at approximately $1,595,700. This represents a 8.59 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 15,100 shares of company stock valued at $889,872 over the last 90 days. 7.20% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Vericel

Several institutional investors and hedge funds have recently modified their holdings of VCEL. Mirae Asset Global Investments Co. Ltd. grew its stake in Vericel by 22.2% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,773 shares of the biotechnology company’s stock valued at $77,000 after acquiring an additional 322 shares in the last quarter. Farther Finance Advisors LLC grew its position in shares of Vericel by 48.1% during the third quarter. Farther Finance Advisors LLC now owns 1,247 shares of the biotechnology company’s stock valued at $53,000 after purchasing an additional 405 shares in the last quarter. PFG Investments LLC increased its holdings in shares of Vericel by 8.0% in the third quarter. PFG Investments LLC now owns 7,400 shares of the biotechnology company’s stock worth $313,000 after purchasing an additional 550 shares during the last quarter. International Assets Investment Management LLC lifted its position in shares of Vericel by 4,126.7% in the third quarter. International Assets Investment Management LLC now owns 634 shares of the biotechnology company’s stock worth $27,000 after buying an additional 619 shares in the last quarter. Finally, Advisors Asset Management Inc. boosted its stake in Vericel by 4.0% during the third quarter. Advisors Asset Management Inc. now owns 16,890 shares of the biotechnology company’s stock valued at $714,000 after buying an additional 644 shares during the last quarter.

Vericel Company Profile

(Get Free Report)

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.

Read More

Earnings History and Estimates for Vericel (NASDAQ:VCEL)

Receive News & Ratings for Vericel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel and related companies with MarketBeat.com's FREE daily email newsletter.